Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma

被引：10

作者：

Bajetta, Emilio ^{[1
]}

机构：

[1] Fdn IRCCS, Ist Nazl Tumori, I-20133 Milan, Italy

来源：

NATURE CLINICAL PRACTICE ONCOLOGY | 2008年 / 5卷 / 01期

关键词：

D O I：

10.1038/ncponc1007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：4 / 5

页数：2

共 11 条

[1] MULTICENTER RANDOMIZED TRIAL OF DACARBAZINE ALONE OR IN COMBINATION WITH 2 DIFFERENT DOSES AND SCHEDULES OF INTERFERON ALFA-2A IN THE TREATMENT OF ADVANCED MELANOMA [J].

BAJETTA, E ;

DILEO, A ;

ZAMPINO, MG ;

SERTOLI, MR ;

COMELLA, G ;

BARDUAGNI, M ;

GIANNOTTI, B ;

QUEIROLO, P ;

TRIBBIA, G ;

BERNENGO, MG ;

MENICHETTI, ET ;

PALMERI, S ;

RUSSO, A ;

CRISTOFOLINI, M ;

ERBAZZI, A ;

FOWST, C ;

CRISCUOLO, D ;

BUFALINO, R ;

ZILEMBO, N ;

CASCINELLI, N .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :806-811

[2]

Bajetta E, 1998, CLIN CANCER RES, V4, P75

[3] Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma [J].

Bajetta, E ;

Del Vecchio, M ;

Nova, P ;

Fusi, A ;

Daponte, A ;

Sertoli, MR ;

Queirolo, P ;

Taveggia, P ;

Bernengo, MG ;

Legha, SS ;

Formisano, B ;

Cascinelli, N .

ANNALS OF ONCOLOGY, 2006, 17 (04) :571-577

[4] Prognostic significance of autoimmunity during treatment of melanoma with interferon [J].

Gogas, H ;

Ioannovich, J ;

Dafni, U ;

Stavropoulou-Giokas, C ;

Frangia, K ;

Tsoutsos, D ;

Panagiotou, P ;

Polyzos, A ;

Papadopoulos, O ;

Stratigos, A ;

Markopoulos, C ;

Bafaloukos, D ;

Pectasides, D ;

Fountzilas, G ;

Kirkwood, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (07) :709-718

[5] High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190 [J].

Kirkwood, JM ;

Ibrahim, JG ;

Sondak, VK ;

Richards, J ;

Flaherty, LE ;

Ernstoff, MS ;

Smith, TJ ;

Rao, U ;

Steele, M ;

Blum, RH .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2444-2458

[6] Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684 [J].

Kirkwood, JM ;

Strawderman, MH ;

Ernstoff, MS ;

Smith, TJ ;

Borden, EC ;

Blum, RH .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :7-17

[7] High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801 [J].

Kirkwood, JM ;

Ibrahim, JG ;

Sosman, JA ;

Sondak, VK ;

Agarwala, SS ;

Ernstoff, MS ;

Rao, U .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2370-2380

[8] A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma [J].

Kirkwood, JM ;

Manola, J ;

Ibrahim, J ;

Sondak, V ;

Ernstoff, MS ;

Rao, U .

CLINICAL CANCER RESEARCH, 2004, 10 (05) :1670-1677

[9] Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials [J].

Lens, MB ;

Dawes, M .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1818-1825

[10] Malignant melanoma in the 21st century, part 2: Staging, prognosis, and treatment [J].

Markovic, Svetomir N. ;

Erickson, Lori A. ;

Rao, Ravi D. ;

Weenig, Roger H. ;

Pockaj, Barbara A. ;

Bardia, Aditya ;

Vachon, Celine M. ;

Schild, Steven E. ;

Mcwilliams, Robert R. ;

Hand, Jennifer L. ;

Laman, Susan D. ;

Kottschade, Lisa A. ;

Maples, William J. ;

Pittelkow, Mark R. ;

Pulido, Jose S. ;

Cameron, J. Douglas ;

Creagan, Edward T. .

MAYO CLINIC PROCEEDINGS, 2007, 82 (04) :490-513

← 1 2 →